GleamWall
中文EN

XTLB XTL BIOPHARMACEUTICALS LTD IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1023549

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY42.4%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin0.7%
Operating margin-481.6%
Net margin-227.7%
FCF margin-370.7%
EBITDA margin—

Returns

ROE-26.8%
ROA-18.7%
ROIC (approx.)-58.3%
Asset turnover0.08x

Leverage & solvency

Liabilities / assets36.4%
Debt / equity0.00x
Current ratio0.61x
Interest coverage-77.57x

Cash quality & payout

Operating cash flow / net income1.58x
Accruals ratio10.8%
Payout ratio—
Capex / revenue12.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2024*2024-12-31FY2023*2023-12-31
Income statement
Revenue$451,000—
Cost of revenue$448,000—
Gross profit$3,000—
R&D expense$98,000$31,000
SG&A expense$1.59M$734,000
Operating income-$2.17M-$765,000
Interest expense$28,000—
Pretax income-$1.16M-$1.78M
Income tax-$130,000—
Net income-$1.03M-$1.78M
EPS (basic)-0.00-0.00
EPS (diluted)-0.00-0.00
Weighted avg. shares (diluted)704.16M544.91M
Balance sheet
Cash & equivalents$371,000$1.40M
Receivables$99,000—
Current assets$1.34M$2.05M
PP&E, netmay include right-of-use assets (IFRS)$187,000—
Goodwill$3.19M—
Intangibles$3.82M$380,000
Total assets$8.55M$2.43M
Current liabilities$2.21M$206,000
Short-term debt$138,000—
Total liabilities$3.12M$206,000
Shareholders' equity$5.43M$2.22M
Shares outstanding881.39M544.91M
Cash flow statement
Operating cash flow-$1.62M-$707,000
Capital expenditure$54,000—
Free cash flow-$1.67M—
Investing cash flow-$844,000$41,000
Financing cash flow$1.45M—
Stock-based compensation$264,000$3,000

Free plan shows the latest 2 periods; Pro shows all 10 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.